Shots:
Ahsan spoke about the US FDA acceptance for Priority Review of sBLAs for PADCEV and KEYTRUDA to treat patients with LA/mUC who are not eligible to receive cisplatin-containing CT
He also talked about the study design and outcomes from the P-Ib/II (EV-103) clinical trial that supported the sBLA. The results from Dose Escalation/Cohort A…
Shots:
The US FDA approved 6 NDAs and 4 BLA in April 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 36 novel products in 2023
In April 2023, the major highlights drugs were, Trikafta approval for children with cystic fibrosis, Qalsody for the treatment of amyotrophic…
“Get Informed, Get Screened, Get Vaccinated” – WHO
Introduction:
Cervical cancer is the 4th most common cancer among women and 7th most commonly occurring cancer overall. When a malignant growth or tumor occurs in the cells lining the walls of the cervix, it is called cervical cancer. The cervix is the narrow, lower part of the uterus…
Shots:
The pharmaceutical companies have shown continual efforts towards developing enhanced and innovative treatment options to address the unmet needs of patients with disease eradication being the goal of developing these treatments
Advancements in cellular and molecular biology have increased the possibilities for generating new pharmaceutical products imposing major impacts on the prevention, diagnosis, and…
Active Ingredients: Pembrolizumab
Strength: 100 mg/4 mL (25 mg/mL)
Dosage Form: Syringe, Vial
Mechanism of Action: PD-1 ligands antagonists
First Approval: US (Sep 4, 2014), EU (Jul 17, 2015)
Revenue
Keytruda (pembrolizumab) has been a key player in Merck & Co. immuno-oncology drugs for the past years – reaching nearly $17B in annual sales in 2021. Despite the dampening impact…
Active Ingredients: Adalimumab
Strength: 40 mg/0.8 ml
Dosage Form: Syringe, Vial
Mechanism of Action: TNF-alpha inhibitors
First Approval: US (Dec 31, 2002), EU (Aug 09, 2003)
Revenue
Humira (adalimumab) has been the top-selling biologic drug product for the last few years – reaching nearly $21B in annual sales in 2021. Humira is one of the main drivers of AbbVie’s immunology…
The year 2021 witnessed the global approval of vaccines and drugs amid COVID-19. The disease has been dominating the headlines from the last two years.
No one is amazed that COVID vaccines and drugs find a place in top selling drugs this time. Pfizer & BioNTech’s Comirnaty took the first position with $36B revenue and…
Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012
The Breakthrough Designation is granted to the drug candidates as monotherapy or in combination with other drugs intended to treat serious or life-threatening diseases and has shown substantial improvement over available…
The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology- cardiology- and neurology but are they…

